TWYNSTA TABLET

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

TELMISARTAN; AMLODIPINE (AMLODIPINE BESYLATE)

可用日期:

BOEHRINGER INGELHEIM (CANADA) LTD LTEE

ATC代码:

C09DB04

INN（国际名称）:

TELMISARTAN AND AMLODIPINE

剂量:

80MG; 5MG

药物剂型:

TABLET

组成:

TELMISARTAN 80MG; AMLODIPINE (AMLODIPINE BESYLATE) 5MG

给药途径:

ORAL

每包单位数:

14/28

处方类型:

Prescription

治疗领域:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

產品總結:

Active ingredient group (AIG) number: 0252947003; AHFS:

授权状态:

APPROVED

授权日期:

2011-08-03

产品特点

_ _
_Product Monograph _
_ _
_TWYNSTA (telmisartan/amlodipine) _
_Page 1 of 54 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
TWYNSTA
®
Telmisartan / Amlodipine (as Amlodipine Besylate) Tablets
Tablet, 40/5 mg, 40/10 mg, 80/5 mg, 80/10 mg, Oral
Angiotensin II AT1 Receptor Blocker / Calcium Channel Blocker
Boehringer Ingelheim (Canada) Ltd.
5180 South Service Road
Burlington, Ontario
L7L 5H4
Date of Initial Authorization:
AUG 11, 2011
Date of Revision:
October 4, 2022
Submission Control Number: 264045
BICL CCDS# 0275-08
Twynsta
®
is a registered trademark used under license by Boehringer Ingelheim
(Canada) Ltd.
_ _
_Product Monograph _
_ _
_TWYNSTA (telmisartan/amlodipine) _
_Page 2 of 54 _
RECENT MAJOR LABEL CHANGES
4 DOSAGE AND ADMINISTRATION
10/2022
7 WARNINGS AND PRECAUTIONS
10/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL
CHANGES............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
..........................................................................................................
4
1.2
Geriatrics...........................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................ 5
4
DOSAGE AND
ADMINISTRATION.................................................................................
5
4.2
Recommended Dose and Dosage
Adjustment.......